Abstract:ABSTRACT Of the approximately 10 million cases of Mycobacterium tuberculosis ( Mtb ) infections each year, over 10% are resistant to the frontline antibiotic isoniazid (INH). INH resistance is predominantly caused by mutations that decrease the activity of the bacterial enzyme KatG, which mediates the conversion of the pro-drug INH to its active form INH-NAD. We previously discovered an inhibitor of Mtb respiration, C10, that enhances the bactericidal activity of INH, prevents the emergence of INH-resistant mutants, and re-sensitizes a collection of INH-resistant mutants to INH through an unknown mechanism. To investigate the mechanism of action of C10, we exploited the toxicity of high concentrations of C10 to select for resistant mutants. We discovered two mutations that confer resistance to the disruption of energy metabolism and allow for the growth of Mtb in high C10 concentrations, indicating that growth inhibition by C10 is associated with inhibition of respiration. Using these mutants as well as direct inhibitors of the Mtb electron transport chain, we provide evidence that inhibition of energy metabolism by C10 is neither sufficient nor necessary to potentiate killing by INH. Instead, we find that C10 acts downstream of INH-NAD synthesis, causing Mtb to become particularly sensitive to inhibition of the INH-NAD target, InhA, without changing the concentration of INH-NAD or the activity of InhA, the two predominant mechanisms of potentiating INH. Our studies revealed that there exists a vulnerability in Mtb that can be exploited to render Mtb sensitive to otherwise subinhibitory concentrations of InhA inhibitor. IMPORTANCE Isoniazid (INH) is a critical frontline antibiotic to treat Mycobacterium tuberculosis ( Mtb ) infections. INH efficacy is limited by its suboptimal penetration of the Mtb -containing lesion and by the prevalence of clinical INH resistance. We previously discovered a compound, C10, that enhances the bactericidal activity of INH, prevents the emergence of INH-resistant mutants, and re-sensitizes a set of INH-resistant mutants to INH. Resistance is typically mediated by katG mutations that decrease the activation of INH, which is required for INH to inhibit the essential enzyme InhA. Our current work demonstrates that C10 re-sensitizes INH-resistant katG -hypomorphs without enhancing the activation of INH. We furthermore show that C10 causes Mtb to become particularly vulnerable to InhA inhibition without compromising InhA activity on its own. Therefore, C10 represents a novel strategy to curtail the development of INH resistance and to sensitize Mtb to sub-lethal doses of INH, such as those achieved at the infection site.

PatA Regulates Isoniazid Resistance by Mediating Mycolic Acid Synthesis and Controls Biofilm Formation by Affecting Lipid Synthesis in Mycobacteria

The past, present and future of tuberculosis treatment.

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition

Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug-resistant Mycobacterium tuberculosis

Regulation of Mycobacterium biofilm development and novel measures against antibiotics resistance

Azetidines Kill Multidrug-Resistant Mycobacterium tuberculosis without Detectable Resistance by Blocking Mycolate Assembly

Mutations in Dnaa and a Cryptic Interaction Site Increase Drug Resistance in Mycobacterium Tuberculosis.

Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

An Extensive Computational Investigation of Mycobacterium tuberculosis Pantothenate Synthetase Inhibitors from Diverse‐Lib Compounds Library

Mechanistic Insights into the Conformational Changes and Alterations in Residual Communications Due to the Mutations in the pncA Gene of Mycobacterium tuberculosis : A Computational Perspective for Effective Therapeutic Solutions

Effect of Isoniazid Resistance on Pathogenicity of Mycobacterium tuberculosis Revealed by Oligonucleotide Microarray Profiling

Quantitative proteomics reveals novel insights into isoniazid susceptibility in mycobacteria mediated by a universal stress protein.

Current research progress on acid resistance mechanism of Mycobacterium tuberculosis

Cyclic Di-Gmp Regulates Mycobacterium Tuberculosis Resistance to Ethionamide

Aspartate Decarboxylase (pand) As a New Target of Pyrazinamide in Mycobacterium Tuberculosis.

The Role of Mycobacterium Tuberculosis Acetyltransferase and Protein Acetylation Modifications in Tuberculosis

Deletion of the Mycobacterium tuberculosis cyp138 gene leads to changes in membrane-related lipid composition and antibiotic susceptibility

The Wag31 Protein Interacts with AccA3 and Coordinates Cell Wall Lipid Permeability and Lipophilic Drug Resistance in Mycobacterium Smegmatis.

The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis